PressDecember 15, 2023 Cedar Clinical Research Selected as Clinical Research Site for Beckley Psytech’s Phase 2b Study
PressDecember 14, 2023 Beckley Academy Welcomes New Faculty for 2024 Psychedelic Therapy Practitioners Courses
PressDecember 14, 2023 Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
PressDecember 14, 2023 MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
PressDecember 14, 2023 Sunstone Therapies Celebrates Three Year Anniversary With More Than 100 Psychedelic-Assisted Therapy Treatments Completed
PressDecember 12, 2023 MAPS PBC Announces Submission of New Drug Application to the FDA for MDMA-Assisted Therapy for PTSD
PressDecember 12, 2023 Rose Hill and ACS Laboratory Join Forces to Pioneer Psilocybin Testing Standards
PressDecember 12, 2023 Psyched Wellness’s Calm, First Legal Amanita Muscaria Extract, Arrives at Pop-up Grocer in NYC
PressDecember 11, 2023 Beckley Retreats Announces Expanded Scholarship Program, Alongside New Specialty Programs for Underserved Communities
PressDecember 11, 2023 Red Light Holland’s GMP Manufactured Psilocybin Microdosing Capsules Aimed to Be Distributed in Emerging Markets Pass Five Month Stability Testing by CCrest Laboratories in Montreal, Canada
PressDecember 11, 2023 Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
PressDecember 6, 2023 Filament Health Announces signing of definitive agreement for convertible note financing, closing of $900,000 non-brokered private placement financing
PressDecember 6, 2023 Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
PressDecember 5, 2023 Mental Health Psychedelic Apps Market is Booming & Expected to Grow at a CAGR of 19.2% to 2031
PressDecember 1, 2023 Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
PressDecember 1, 2023 Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
PressNovember 30, 2023 Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update
PressNovember 30, 2023 Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
